Q-omics provides the consensus-scored DHRS7C profile across patient tissues and cancer cell-line models. DHRS7C expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, DHRS7C is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, DHRS7C RNA expression shows 9,192 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUAD, COAD, and TGCT as cancer lineages where DHRS7C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DHRS7C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DHRS7C survival associations across molecular data types. DHRS7C RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DHRS7C RNA expression–survival associations across cancer types. High DHRS7C expression shows unfavorable associations in LUAD, KICH, THYM, MESO and TGCT, but favorable associations in KIRC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for DHRS7C RNA expression.
This table summarizes DHRS7C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for DHRS7C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DHRS7C shows lower tumor expression in COAD, BLCA, HNSC, READ and LIHC and higher tumor expression in KIRC. The COAD box plot shows higher DHRS7C RNA expression in normal versus tumor tissue (log2 FC = −1.264, t-test p < 0.001).
This table shows molecular features associated with DHRS7C in patient tissues and cancer cell lines. In patient samples, DHRS7C shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, DHRS7C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and PANCREAS.
